(AGS-16C3F-12-2) A Phase I, Open-Label, Multi-Center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects with Renal Cell Carcinoma of Clear Cell or Papillary Histology
Description: 

This is a multi-center, open-label study in subjects with metastatic RCC (renal cell carcinoma) with clear cell or non-clear cell histology. Subjects with clear cell or non-clear cell papillary histology must have ENPP3 positive immunohistochemical (IHC) staining at prescreening.

Study Number: 

PH 221212

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01672775

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.